ID   H446/EP
AC   CVCL_RT18
DR   cancercelllines; CVCL_RT18
DR   Wikidata; Q54872146
RX   PubMed=28599409;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Gene fusion; HGNC; 6728; LY6H + HGNC; 9709; PVT1; Name(s)=PVT1-LY6H (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Val (c.461G>T); ClinVar=VCV000651769; Zygosity=Homozygous (from parent cell line).
CC   Omics: miRNA expression profiling.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1562 ! NCI-H446
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 11
//
RX   PubMed=28599409; DOI=10.3892/ol.2017.5967;
RA   Chen Y.-T., Yang X., Xu Y.-C., Cao J.-R., Chen L.-B.;
RT   "Genomic analysis of drug resistant small cell lung cancer cell lines
RT   by combining mRNA and miRNA expression profiling.";
RL   Oncol. Lett. 13:4077-4084(2017).
//